Encouraging Guidance on Clinical Program Makes Summit Therapeutics (SMMT) Look Attractive

Summit Therapeutics (NASDAQ:SMMT) is one of the best large cap stocks under $100 with huge upside potential. On January 14, H.C. Wainwright analyst Mitchell Kapoor reaffirmed his optimistic outlook on Summit Therapeutics (NASDAQ:SMMT). He assigned a Buy rating to the stock with a $40 price target, resulting in an upside of nearly 143%. Copyright: dolgachov / 123RF Stock Photo Kapoor’s rating comes at the back of the company’s submission of Biologics License Application (BLA), relating to ivonescimab cl ...